Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Adenosine Deaminase-Severe Combined Immunodeficiency Market Grown from 2024 to 2025?
In recent times, there has been a robust increase in the market size of adenosine deaminase-severe combined immunodeficiency. The market which was valued at $5.57 billion in 2024 is projected to reach $5.95 billion in 2025, signifying a compound annual growth rate (CAGR) of 6.9%. The increase during the past period could be linked to a higher occurrence rate of severe combined immunodeficiency, climbing PID incidents, an upsurge in prevalence of immunodeficiencies, escalated investments in healthcare, and growing consciousness about immunodeficiencies.
What Growth Rate Is Anticipated for the Adenosine Deaminase-Severe Combined Immunodeficiency Market in the Coming Years?
The market for adenosine deaminase-severe combined immunodeficiency is poised for robust growth in the coming years. By 2029, the market is expected to balloon to $7.70 billion, marking a compound annual growth rate (CAGR) of 6.6%. This overall growth trend can be linked to several factors including an uptick in genetic disorders, a rise in bone marrow transplantation, burgeoning demand for non-conditioned stem cell transplants, an increase in ADA deficiency instances, and a growing number of cases of adenosine deaminase deficiency (PDA). Looking ahead, key trends that could shape the market include technological innovation, the embracing of gene therapy, government-led initiatives, advancements in genetic testing, and breakthroughs in the field of biotechnology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21085&type=smp
Who Are the Leading Companies in the Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc, Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, QED Bioscience Inc.
What Are the Key Drivers of the Adenosine Deaminase-Severe Combined Immunodeficiency Market?
The upsurge in genetic disorders is anticipated to fuel the expansion of the adenosine deaminase-severe combined immunodeficiency market in the future. Genetic disorders are medical conditions triggered by irregularities or mutations in a person’s DNA, either inherited or spontaneously occurring. Factors, like improved diagnostic tools, heightened awareness, increased parental age, environmental factors, and population growth, drive the escalating prevalence of genetic disorders. This increase, especially in disorders like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), necessitates the growth in demand for progressive diagnostic procedures and targeted treatment methods. For instance, a report from the Department of Health & Social Care (DHSC), a UK government department, revealed in December 2022 that approximately 33,000 whole genome equivalents were sequenced by October 2022. The average diagnostic yield was 32%, which increased to 61% in particular conditions. Hence, the mounting prevalence of genetic disorders is propelling the growth of the adenosine deaminase-severe combined immunodeficiency market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21085&type=smp
What Are the Key Market Segments in the Adenosine Deaminase-Severe Combined Immunodeficiency Industry?
The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –
1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Age Group: Pediatric (Infants and Children), Adults
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement, Pegylated Erythropoietin (PEG-EPO)
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support, Nutritional Support
What Are the Latest Trends in the Adenosine Deaminase-Severe Combined Immunodeficiency Market?
Leading firms in the adenosine deaminase-severe combined immunodeficiency marketplace are honing in on progressive treatments like gene therapy for uncommon conditions in order to improve therapeutic results, boost patient longevity, and resolve the fundamental genetic origins of the disease using cutting-edge medical technology. The objective of gene therapy in the context of adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is to rectify the genetic defect by infusing a functional ADA gene, promising a potential long-lasting cure for this rare and fatal immunological malady. An example of this is Danaher Corporation, a pioneer in life sciences and diagnostics based in the US, which became part of the Bespoke Gene Therapy Consortium (BGTC) in May 2022 as a component of the Accelerating Medicines Partnership (AMP) initiative. Working with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical firms, and non-profit entities, the aim of this scheme is to advance tailored gene therapies for rare maladies and bolster development efficiency. This collaboration is particularly momentous as it embodies a shared commitment to surmount the hurdles of traditional pharmaceutical development for rare diseases—ailments that frequently garner scarce commercial attention owing to their low incidence rates.
Access The Full Report Here:
What Are the Key Regional Markets in the Adenosine Deaminase-Severe Combined Immunodeficiency Industry?
North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21085
This Report Delivers Insight On:
1. How big is the adenosine deaminase-severe combined immunodeficiency market, and how is it changing globally?
2. Who are the major companies in the adenosine deaminase-severe combined immunodeficiency market, and how are they performing?
3. What are the key opportunities and risks in the adenosine deaminase-severe combined immunodeficiency market right now?
4. Which products or customer segments are growing the most in the adenosine deaminase-severe combined immunodeficiency market?
5. What factors are helping or slowing down the growth of the adenosine deaminase-severe combined immunodeficiency market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model